Alternatives to Aelis Farma
Aelis Farma is a Biotechnology tool: clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Aelis Farma
- Website AMAmbrx35BiotechnologySan Diego, United States$461.5M
Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.
- Website
Ipsen33BiotechParis, FranceGlobal biopharmaceutical company focused on oncology, rare diseases, and neuroscience.
- Website
Braeburn44BiotechPlymouth Meeting, United States$133.0MDevelops long-acting implantable and injectable therapies for opioid addiction and chronic pain.
- Website
Ethypharm58PharmaceuticalsSaint-Cloud, France$557KInternational specialty pharmaceutical company focused on central nervous system, pain management, and addiction treatments.
- Website
Indivior11PharmaceuticalsSlough, United KingdomPharmaceutical company focused on addiction treatment and mental health.
- Website ZYZynerba Pharmaceuticals38BiotechWayne, United States
Pharmaceutical company developing transdermal cannabinoid therapeutics for behavioral and emotional conditions.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Verdiva Bio54BiotechnologySan Diego, United States$170.0MClinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.
Showing the 20 closest matches. See the rest on the Aelis Farma profile.
Compare Aelis Farma head to head
Side by side on what each one does, what it costs, and what real users report.